CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA infection

Migration of leukocytes to the site of microbial infection is important for the development of effective host immunity. Recombinant modified vaccinia virus Ankara is frequently used as a viral vector vaccine in preclinical and clinical studies. In comparison to other vaccinia virus strains, modified vaccinia virus Ankara robustly induces chemokine expression and rapid attraction of leukocytes. In particular, chemokine (C‐C motif) ligand 2 (CCL2) has been shown to be critical for leukocyte recruitment to the lung. In this study, MVA‐induced CCL2 expression in murine macrophages was dependent on type I interferon receptor and not Toll‐like receptor‐2. The critical role of type I interferon receptor signaling for CCL2 production in the lung was confirmed in type I interferon receptor–deficient mice (Ifnar1−/−). In addition, comparing Ifnar1−/− and Ccl2−/− mice with wild‐type mice, we observed a similar impairment in the recruitment of natural killer and T cells to the lung after intranasal infection with modified vaccinia virus Ankara. Conversely, neutrophil recruitment was not affected in Ifnar1−/− and Ccl2−/− mice. We conclude that type I interferons, besides their known antiviral properties, can initiate the recruitment and activation of leukocytes via induction of chemokine expression including CCL2.

[1]  A. Alcamí,et al.  Immune modulation by virus-encoded secreted chemokine binding proteins. , 2015, Virus research.

[2]  S. Eo,et al.  Distinct Upstream Role of Type I IFN Signaling in Hematopoietic Stem Cell-Derived and Epithelial Resident Cells for Concerted Recruitment of Ly-6Chi Monocytes and NK Cells via CCL2-CCL3 Cascade , 2015, PLoS pathogens.

[3]  S. Salek-Ardakani,et al.  Natural Killer Cells and Innate Interferon Gamma Participate in the Host Defense against Respiratory Vaccinia Virus Infection , 2015, Journal of Virology.

[4]  Abigail Hielscher,et al.  The mechanisms of genetically modified vaccinia viruses for the treatment of cancer. , 2015, Critical reviews in oncology/hematology.

[5]  S. Akira,et al.  Alveolar macrophage–derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes , 2015, The Journal of experimental medicine.

[6]  G. Pantaleo,et al.  NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses , 2015, Proceedings of the National Academy of Sciences.

[7]  Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage , 2015, Virology Journal.

[8]  G. Sutter,et al.  Complement Component C5 Recruits Neutrophils in the Absence of C3 during Respiratory Infection with Modified Vaccinia Virus Ankara , 2015, The Journal of Immunology.

[9]  G. Cheng,et al.  Positive feedback regulation of type I interferon by the interferon‐stimulated gene STING , 2015, EMBO reports.

[10]  G. Rimmelzwaan,et al.  Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. , 2014, The Lancet. Infectious diseases.

[11]  M. Seshadri,et al.  CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells , 2014, The Journal of Immunology.

[12]  T. Murayama,et al.  Human cytomegalovirus replication supported by virus-induced activation of CCL2-CCR2 interactions. , 2014, Biochemical and biophysical research communications.

[13]  A. Bowie,et al.  Innate immune activation of NFκB and its antagonism by poxviruses. , 2014, Cytokine & growth factor reviews.

[14]  G. Sutter,et al.  Chemokine (C-C Motif) Receptor 1 Is Required for Efficient Recruitment of Neutrophils during Respiratory Infection with Modified Vaccinia Virus Ankara , 2014, Journal of Virology.

[15]  Zhijian J. Chen,et al.  Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway , 2014, PLoS pathogens.

[16]  H. Reyburn,et al.  Differential Induction of Apoptosis, Interferon Signaling, and Phagocytosis in Macrophages Infected with a Panel of Attenuated and Nonattenuated Poxviruses , 2014, Journal of Virology.

[17]  C. Maluquer de Motes,et al.  Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. , 2013, The Journal of general virology.

[18]  C. Garlanda,et al.  Tumor associated macrophages and neutrophils in cancer. , 2013, Immunobiology.

[19]  M. Esteban,et al.  Clinical applications of attenuated MVA poxvirus strain , 2013, Expert review of vaccines.

[20]  R. Schmidt,et al.  Multifaceted Impact of Host C–C Chemokine CCL2 in the Immuno-Pathogenesis of HIV-1/M. tuberculosis Co-Infection , 2013, Front. Immunol..

[21]  G. Sutter,et al.  Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. , 2013, Vaccine.

[22]  S. Kotenko,et al.  Interferon induction and function at the mucosal surface , 2013, Immunological reviews.

[23]  J. Arthur,et al.  IFNβ autocrine feedback is required to sustain TLR induced production of MCP-1 in macrophages , 2013, FEBS letters.

[24]  V. Rivera-Amill,et al.  Astrocytic expression of HIV-1 Nef impairs spatial and recognition memory , 2013, Neurobiology of Disease.

[25]  T. Decker,et al.  The regulation of inflammation by interferons and their STATs , 2013, JAK-STAT.

[26]  Christopher D. Conrady,et al.  IFN-α-driven CCL2 Production Recruits Inflammatory Monocytes to Infection Site in Mice , 2012, Mucosal Immunology.

[27]  Interleukin-1β receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1β activity produced in various virus-infected antigen-presenting cells , 2013, Virology Journal.

[28]  D. Zaiss,et al.  CCR2 Defines a Distinct Population of NK Cells and Mediates Their Migration during Influenza Virus Infection in Mice , 2012, PloS one.

[29]  D. Bartlett,et al.  Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. , 2012, Neoplasia.

[30]  D. Duffy,et al.  Neutrophils transport antigen from the dermis to the bone marrow, initiating a source of memory CD8+ T cells. , 2012, Immunity.

[31]  Y. Iwakura,et al.  Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcγR signaling , 2012, Proceedings of the National Academy of Sciences.

[32]  Xiaoliu Zhang,et al.  Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  J. Kreijtz,et al.  Easy and efficient protocols for working with recombinant vaccinia virus MVA. , 2012, Methods in molecular biology.

[34]  Oncolytic poxviruses , 2012, Molecular Genetics, Microbiology and Virology.

[35]  A. Bowie,et al.  Vaccinia Virus Protein C6 Is a Virulence Factor that Binds TBK-1 Adaptor Proteins and Inhibits Activation of IRF3 and IRF7 , 2011, PLoS pathogens.

[36]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[37]  S. Akira,et al.  Pathogen Recognition by the Innate Immune System , 2011, International reviews of immunology.

[38]  Vandana Saini,et al.  MCP-1: chemoattractant with a role beyond immunity: a review. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[39]  R. Locksley,et al.  Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands , 2009, Nature Immunology.

[40]  Heather E. Lynch,et al.  Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication. , 2009, Virology.

[41]  T. Salazar-Mather,et al.  Regulation of Inflammatory Monocyte/Macrophage Recruitment from the Bone Marrow during Murine Cytomegalovirus Infection: Role for Type I Interferons in Localized Induction of CCR2 Ligands1 , 2009, The Journal of Immunology.

[42]  S. Akira,et al.  Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome , 2009, PLoS pathogens.

[43]  W. Kastenmuller,et al.  Modified Vaccinia Virus Ankara Triggers Chemotaxis of Monocytes and Early Respiratory Immigration of Leukocytes by Induction of CCL2 Expression , 2009, Journal of Virology.

[44]  J. Löwer,et al.  Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. , 2009, The Journal of infectious diseases.

[45]  L. Anderson,et al.  Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2 , 2008, Journal of Virology.

[46]  S. Akira,et al.  Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. , 2008, The Journal of clinical investigation.

[47]  S. Akira,et al.  Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses , 2007, Journal of Virology.

[48]  T. Gallart,et al.  Distinct Gene Expression Profiling after Infection of Immature Human Monocyte-Derived Dendritic Cells by the Attenuated Poxvirus Vectors MVA and NYVAC , 2007, Journal of Virology.

[49]  T. Hartung,et al.  Cellular Recognition of Trimyristoylated Peptide or Enterobacterial Lipopolysaccharide via Both TLR2 and TLR4* , 2007, Journal of Biological Chemistry.

[50]  S. Kramer,et al.  HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin-dependent manner , 2006, Journal of Cell Science.

[51]  W. Seeger,et al.  Alveolar Epithelial Cells Direct Monocyte Transepithelial Migration upon Influenza Virus Infection: Impact of Chemokines and Adhesion Molecules1 , 2006, The Journal of Immunology.

[52]  A. Bowie,et al.  Poxvirus Protein N1L Targets the I-κB Kinase Complex, Inhibits Signaling to NF-κB by the Tumor Necrosis Factor Superfamily of Receptors, and Inhibits NF-κB and IRF3 Signaling by Toll-like Receptors* , 2004, Journal of Biological Chemistry.

[53]  J. Shisler,et al.  The Vaccinia Virus K1L Gene Product Inhibits Host NF-κB Activation by Preventing IκBα Degradation , 2004, Journal of Virology.

[54]  Charles L. Bailey,et al.  Prevention of lethal respiratory vaccinia infections in mice with interferon-α and interferon-γ , 2004 .

[55]  R. Bronson,et al.  Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Shisler,et al.  The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. , 2004, Journal of virology.

[57]  Charles L. Bailey,et al.  Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma. , 2004, FEMS immunology and medical microbiology.

[58]  A. Bowie,et al.  Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. , 2004, The Journal of biological chemistry.

[59]  G. McFadden,et al.  Poxviruses and immune evasion. , 2003, Annual review of immunology.

[60]  Steffen Jung,et al.  Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.

[61]  C. Staib,et al.  Improved host range selection for recombinant modified vaccinia virus Ankara. , 2003, BioTechniques.

[62]  A. Alcamí,et al.  The Vaccinia Virus Soluble Alpha/Beta Interferon (IFN) Receptor Binds to the Cell Surface and Protects Cells from the Antiviral Effects of IFN , 2000, Journal of Virology.

[63]  E. M. Rogers,et al.  Nuclear factor-kappa B p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. , 1999, Journal of immunology.

[64]  M. Rothe,et al.  Human Toll-like Receptor 2 Confers Responsiveness to Bacterial Lipopolysaccharide , 1998, The Journal of experimental medicine.

[65]  M Aguet,et al.  Functional role of type I and type II interferons in antiviral defense. , 1994, Science.

[66]  H. W. Chang,et al.  The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Jordan Interstitial pneumonia and subclinical infection after intranasal inoculation of murine cytomegalovirus , 1978, Infection and immunity.